A single dose of the Pfizer / BioNTech coronavirus vaccine could prevent 75 percent of asymptomatic infections, a study by NHS staff has suggested.
Asymptomatic screening of staff at Addenbrooke ‘s Hospital in Cambridge showed that the number of people undergoing a positive test fell from 0.8 per cent to 0.2 per cent 12 days after the injection.
The ‘very impressive’ decisions are another sign that the UK gamble wants to delay the second dose in a bid to get wider coverage more quickly on pay.
Prevention of asymptomatic diseases is crucial to stop a breakdown from becoming unconscious because people who do not feel ill are less likely to self-destruct.
Several studies had shown that a single injection of the Pfizer injection prevented severe illness and death but to what extent it prevented asymptomatic transmission was unclear. Research has also suggested that Oxford University injections stop more than 60 percent of asymptomatic cases.
The study, led by Cambridge University, analyzed thousands of weekly Covid tests at Cambridge University Hospitals NHS Foundation Trust in January.
It found that 26 out of 3,252 swabs (0.8 percent) from non-vaccinated workers yielded a positive result, compared with four out of 1,989 (0.2 percent) in 12-day workers or more after their vaccination.
The study, which has not yet been peer-reviewed, found that asymptomatic infection was cut in half in those who received the vaccine for less than 12 days, suggesting that immunity kicks in quickly. in many cases.
Independent experts dealing with the pre-emption said the findings, saying they signaled Britain was on its head for a ‘brighter future’.
A single dose of the Pfizer / BioNTech coronavirus vaccine could stop 75 per cent of people from spreading the disease, a study by NHS staff has suggested
It found that 26 out of 3,252 swabs (0.8 percent) from non-vaccinated workers yielded a positive result, compared with four out of 1,989 (0.2 percent) in 12-day workers or more after their vaccination
Professor Jonathan Ball, molecular pathologist at the University of Nottingham, said: ‘Such a reduction in infection rates following a single dose of the Pfizer vaccine is very impressive and shows that the vaccine is truly offering a way out of the current constraints and a clearer future.
It will be important to understand whether the reduced risk of disease was played out in all the exposure risk groups in the study, but nonetheless, this remains good news. ‘
Dr Simon Clarke, associate professor of cell microbiology at Reading University, said: ‘In working-age adults, the Pfizer-BioNTech vaccine has good efficacy in preventing asymptomatic infection with the coronavirus Covid-19.
‘This is very important if we are to reduce the spread of people who are unaware that they have the disease.
‘While this is very encouraging, no data have been provided to show how long the impact will last and ongoing monitoring is required in case this protection is compromised.’
He said the inspection is’ responsible for inspecting NHS staff and it appears that no assessment has been made of their previous level of immunity, which may be higher than it was in the general population with the likelihood of health care workers being open at work.
Predisposition to the coronavirus before receiving a dose appears to cause a stronger immune response to the vaccine.
It is also important to remember that these findings cannot be automatically extended to all other vaccines. ‘
Over two weeks between Jan. 18 and 31, Cambridge researchers studied similar numbers of vaccinated and nonvaccinated workers using approximately 4,400 PCR tests per week.
An advanced PCR swab would indicate that even someone who is vaccinated is carrying pieces of the virus in their nose or throat that could be passed on to them.
Reducing Covid transmission is critical to achieving ‘herd immunity’, when so many people are immune to the onset of disease.
The results were then separated to identify unvaccinated workers, and employees who received the vaccine more than 12 days prior to the trial, when immunity begins.
When the team included symbolic healthcare workers, their analyzes showed similar reductions.
Some 56 out of 3,282 (1.7 percent) health care workers without a vaccine were positive, compared with eight out of 1,997 (04 percent) at 12 days or more after vaccination, a decrease four times.
The researchers have released their data prior to peer review because of the urgent need to share information related to the pandemic.
Dr Mike Weekes, an infectious disease specialist at the trust, who led the study, said: ‘This is good news – the Pfizer vaccine not only protects against illness from SARS-CoV-2 but it also helps prevent infection, reducing the potential. to pass on the virus to others.
‘This will be welcome news as we begin to draw a roadmap out of the lock, but we need to remember that vaccination will not provide complete protection for everyone. We still need social pace, face masks, hand hygiene and regular testing to make the pandemic much better under control. ‘
Dr Nick Jones, the study’s first author and expert on infectious diseases in Cambridge, said: ‘This is great news for hospital staff and patients, who can be assured that the disease is -a current major vaccine mechanism protects against asymptomatic viral behavior as well as symbolic disease, thus making hospitals even safer places to be. ‘
The UK drew criticism in January when it pushed back giving second doses of the two vaccines from three weeks to three months because the jobs have never been proven using that dosing rule.
The policy proposal was made by the Joint Committee on Vaccination and Vaccination (JCVI) as the country was engaged in a wide variety of Kent and limited vaccine supply. His goal was to get wider coverage faster.